Access with evidence development in the UK: past experience, current initiatives and future potential
- PMID: 20085392
- DOI: 10.2165/11531410-000000000-00000
Access with evidence development in the UK: past experience, current initiatives and future potential
Abstract
Access with evidence development (AED) describes the general approach of linking some form of access to the healthcare market with the generation of additional evidence relating to the value of the healthcare intervention under evaluation, with an explicit aim of aiding future decision making. A number of health systems around the world are interested in the potential for such schemes. This article looks in detail at the potential for some form of AED in the UK, focusing on the two major decision-making bodies: the Scottish Medicines Consortium in Scotland and the National Institute for Health and Clinical Excellence in England and Wales. We consider past experience with these approaches and current initiatives that are exploring their potential, and speculate as to how these schemes might develop in the future.
Similar articles
-
Access with evidence development: the US experience.Pharmacoeconomics. 2010;28(2):153-62. doi: 10.2165/11531050-000000000-00000. Pharmacoeconomics. 2010. PMID: 20085391
-
Access with evidence development schemes: a framework for description and evaluation.Pharmacoeconomics. 2010;28(2):143-52. doi: 10.2165/11530850-000000000-00000. Pharmacoeconomics. 2010. PMID: 20085390
-
Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems.Pharmacoeconomics. 2010;28(2):113-42. doi: 10.2165/11530820-000000000-00000. Pharmacoeconomics. 2010. PMID: 20085389 Review.
-
Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric?J Clin Oncol. 2010 Jul 10;28(20):3234-8. doi: 10.1200/JCO.2009.26.2758. Epub 2010 May 24. J Clin Oncol. 2010. PMID: 20498408
-
Balancing early access with uncertainties in evidence for drugs authorized by prospective case series - systematic review of reimbursement decisions.Br J Clin Pharmacol. 2018 Jun;84(6):1146-1155. doi: 10.1111/bcp.13531. Epub 2018 Mar 23. Br J Clin Pharmacol. 2018. PMID: 29381234 Free PMC article.
Cited by
-
Single technology appraisal at the UK National Institute for Health and clinical excellence: a source of evidence and analysis for decision making internationally.Pharmacoeconomics. 2010;28(5):347-9. doi: 10.2165/11535680-000000000-00000. Pharmacoeconomics. 2010. PMID: 20402539 No abstract available.
-
Acknowledging patient heterogeneity in economic evaluation : a systematic literature review.Pharmacoeconomics. 2013 Feb;31(2):111-23. doi: 10.1007/s40273-012-0015-4. Pharmacoeconomics. 2013. PMID: 23329430
-
Access with evidence development: the US experience.Pharmacoeconomics. 2010;28(2):153-62. doi: 10.2165/11531050-000000000-00000. Pharmacoeconomics. 2010. PMID: 20085391
-
Principles of design of access with evidence development approaches: a consensus statement from the Banff Summit.Pharmacoeconomics. 2010;28(2):109-11. doi: 10.2165/11530860-000000000-00000. Pharmacoeconomics. 2010. PMID: 20085388 No abstract available.
-
When to wait for more evidence? Real options analysis in proton therapy.Oncologist. 2011;16(12):1752-61. doi: 10.1634/theoncologist.2011-0029. Epub 2011 Dec 6. Oncologist. 2011. PMID: 22147003 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous